Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Viking is developing what might be a game-changing medication in the segment. Viking Therapeutics (NASDAQ: VKTX), a biotech ...

Danish drugmaker Novo Nordisk (NOV: N) has secured a significant advantage in the high-stakes obesity drug market after ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Losing even a moderate amount of weight is associated with reduced progression of diabetes, improved blood pressure and HDL ...

Here are Investing.com’s stocks of the week. Microsoft was one of many tech giants that reported earnings this week, with the company topping profit and revenue expectations. MSFT shares jumped more ...

Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.